Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Paion Deutschland and Lundbeck A/S have agreed to collaborate on the development and marketing of Paion's stroke drug, which is currently in phase III trials.
Subscribe to our email newsletter
The partnership will develop and market the drug outside the US and Canada, where Forest Laboratories holds rights to the treatment.
The compound, desmoteplase, is a blood clot-dissolving agent, and has the potential to treat patients with acute ischemic stroke up to nine hours after onset of symptoms. The only currently available clot-dissolving agent must be administered within three hours of symptom onset; however, approximately 80% of stroke patients arrive at the hospital outside that treatment window. Desmoteplase, with a targeted nine-hour treatment window, could expand the number of patients who receive clot-dissolving therapy significantly.
The ischemic stroke is the most common type of stroke and occurs when an artery in the brain is obstructed by a blood clot.
The alliance allows Paion to move towards its strategic goal to develop into an integrated biopharmaceutical company with commercial capabilities. Lundbeck and Forest will fund the majority of development activities.